{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:28:27Z","timestamp":1758040107516,"version":"3.44.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ahj.2014.10.016","type":"journal-article","created":{"date-parts":[[2014,11,12]],"date-time":"2014-11-12T05:05:25Z","timestamp":1415768725000},"page":"191-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation"],"prefix":"10.1016","volume":"169","author":[{"given":"Amy","family":"Sarma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"O\u2019Donoghue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","article-title":"Cardiovascular diseases (CVDs). Fact sheet","key":"10.1016\/j.ahj.2014.10.016_bb0005"},{"key":"10.1016\/j.ahj.2014.10.016_bb0010","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/CIRCULATIONAHA.111.089243","article-title":"Personalized cardiovascular medicine and drug development: time for a new paradigm","volume":"125","author":"Loscalzo","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2014.10.016_bb0015","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/clpt.2010.286","article-title":"Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009","volume":"89","author":"Kaitin","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ahj.2014.10.016_bb0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphar.2010.00125","article-title":"The grand challenges in cardiovascular drug discovery and development","volume":"1","author":"Ohlstein","year":"2010","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ahj.2014.10.016_bb0025","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrd3405","article-title":"The productivity crisis in pharmaceutical R&D","volume":"10","author":"Pammolli","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ahj.2014.10.016_bb0030","first-page":"1","volume":"5","author":"Roy","year":"2012"},{"key":"10.1016\/j.ahj.2014.10.016_bb0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ahj.2014.10.016_bb0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/clpt.2009.293","article-title":"Deconstructing the drug development process: the new face of innovation","volume":"87","author":"Kaitin","year":"2010","journal-title":"Clin Pharmacol Ther"},{"year":"2012","author":"Desgrousilliers","series-title":"Drug development time is money for some life-and-death for others. Clinovo Clinical Data Solutions","key":"10.1016\/j.ahj.2014.10.016_bb0045"},{"key":"10.1016\/j.ahj.2014.10.016_bb0050","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.10.016_bb0060","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.10.016_bb0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.10.016_bb0075","article-title":"Pfizer plans to abandon heart-drug development","author":"Wang","year":"2008","journal-title":"Wall St J Midwest Ed"},{"key":"10.1016\/j.ahj.2014.10.016_bb0090","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2014.10.016_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2014.09.016","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: executive summary. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines","author":"Amsterdam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2014.10.016_bb0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314006656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870314006656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:52:46Z","timestamp":1757569966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870314006656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0002870314006656"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2014.10.016","relation":{},"ISSN":["0002-8703"],"issn-type":[{"type":"print","value":"0002-8703"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surviving the gauntlet: Modern challenges in cardiovascular drug approval and implementation","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2014.09.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}